Latest news with #KilitchDrugs
Economic Times
31-07-2025
- Business
- Economic Times
Pharma industry to outdo India Inc in 2025 pay hike: Study
Agencies Pharma industry to outdo India Inc in 2025 pay hike: Study New Delhi: Employees in pharma companies are likely to get an increment of 9.6% in 2025, a tad lower than last year but still exceeding the average pay hike of 8.8% projected for corporate India, according to a Deloitte roles like regen medicine researcher (who investigates ways to repair or replace damaged tissues and organs), pharmacovigilance specialist (who ensures the safety of medications and vaccines), real-world evidence scientist (an expert on data analysis and research methods), digital health programme officer and clinical artificial intelligence analysts are likely to get even higher increments, said experts. 'This year's pay hike has been more progressive compared to the previous cycle' for Mankind Pharma, said Prateek Dubey, global chief HR officer at the maker of Asthakind expectorant and Bandy anti-worm chewable tablet. 'This year, stronger business performance and strategic clarity has enabled us to be more generous and differentiated in our approach,' he told pharma industry has had a stable outlook in terms of increments and promotions over the last five years, with average hikes ranging between 9.3% and 9.8%, Deloitte India partner Neelesh Gupta said. The average pay hikes in India Inc in general, meanwhile, has been consistently declining since projected average 2025 increment is 20 basis points (0.2 percentage point) lower than the average for last year. But when it comes to key talent, employees are attracting retention measures that include 1.5 to 1.8 times increments, retention bonus up to 20% of the fixed pay and fast-track careers, Gupta said. The Deloitte study attributes the pharma sector's higher pay hikes compared with India Inc to sustained strong growth outlook over the years and also the emergence of biotech as a hyper growth engine within life hot and new roles within pharma are commanding a pay premium of 10-20% in the market, according to the Pharma has identified critical talent pools that include roles in R&D, regulatory affairs, digital transformation, manufacturing excellence and product management, said pay hike this year for Kilitch Drugs is at par with last year's levels, said whole-time director Bhavin Mukund Mehta, who is also vice-chairman of the Pharmaceuticals Export Promotion Council of India. Kilitch Drugs is giving an around a 9% hike for 2025.'The pharma sector has been offering better hikes than many other sectors due to a combination of strong business performance, high talent demand and the inherent resilience of the industry,' said top performers, the pay hike this year has ranged between 10% and 20%, he added. At Alembic Pharmaceuticals, the hikes this year are ranging between 6% and 10, said CHRO Namita Patwari.
India.com
09-07-2025
- Business
- India.com
India's Pharma War Zone: How Delhi's Bulk Drug Push Is Rattling China
New Delhi: The heat is rising in India's pharmaceutical backrooms. Quiet factories. Long shifts. New chemical reactors humming across Himachal, Gujarat and Telangana. Something has shifted. China, long the uncontested supplier of India's drug ingredients, is suddenly nervous. Its prices are falling. Fast. Some slashed by 50%. This is no coincidence. The trigger? India's Rs 6,940 crore Production-Linked Incentive (PLI) scheme. Launched in March 2020, it was a shot across the bow. And the target: reduce dependence on Chinese Active Pharmaceutical Ingredients (APIs). By December 2024, 48 domestic API projects were sanctioned. Of these, 34 are already operational. Together, they cover 25 key drug molecules. The investment so far? Rs 4,254 crore. But the Chinese are not backing down quietly. They are throwing prices into free fall. Landed costs of certain APIs from China have collapsed far deeper than Indian prices. Take Atorvastatin, used in cholesterol pills, for instance. Indian API prices fell 17% to Rs 10,000 per kg. China pushed it down to Rs 8,000 per kg. That is a 33% crash. Let's understand with another example of Ofloxacin, a broad-spectrum antibiotic. Indian prices dropped from Rs 3,200 to Rs 2,700. China? Rs 2,100. Down 30% in a year. This is price war, not coincidence. Bhavin Mukund Mehta, director of the Kilitch Drugs and Vice Chairman of Pharmexcil, minced no words, 'Even though the PLI has helped reduce the prices of domestically-produced APIs, the Chinese players are undercutting the competition in specific product categories to retain their market share.' Behind the scenes, policymakers are reviewing the PLI's next phase. They are asked industry insiders for help. The mission is to stop China's dumping spree, push for stronger local production and close the gaping supply chain hole exposed during COVID. The Department of Pharmaceuticals is now asking – can India stand on its own chemical legs and can it stop the bleed from Beijing's pricing games? The pressure is on. China still supplies around 70% of India's API imports. India imports about 50% of its total bulk drug needs. That is the strategic choke point the PLI is aiming to break. The scheme covers the production period from FY23 to FY29. But the impact is already being felt. Jatish Sheth, secretary general of the Confederation of Indian Pharmaceutical Industry, sees this as China's last stand. 'It is an expected move from the Chinese exporters to bring down the bulk drugs prices. While their focus is to retain the market share, we believe that this is a temporary phenomenon. We do not expect the Chinese players to keep selling the drugs at such low prices for too long.' He is betting on patience. Indian drugmakers are playing the long game. With new infrastructure, newer molecules and tighter government support, the tide could soon turn. But for now, it is a staring contest across lab benches and import docks. On one side, old Chinese dominance. On the other, rising Indian ambition backed by billions. And in between? A market worth tens of billions and the chemical backbone of the world's pharmacy.
Business Standard
20-05-2025
- Business
- Business Standard
Kilitch Drugs (India) consolidated net profit rises 189.69% in the March 2025 quarter
Sales rise 36.61% to Rs 61.23 crore Net profit of Kilitch Drugs (India) rose 189.69% to Rs 10.40 crore in the quarter ended March 2025 as against Rs 3.59 crore during the previous quarter ended March 2024. Sales rose 36.61% to Rs 61.23 crore in the quarter ended March 2025 as against Rs 44.82 crore during the previous quarter ended March 2024. For the full year,net profit rose 82.88% to Rs 26.70 crore in the year ended March 2025 as against Rs 14.60 crore during the previous year ended March 2024. Sales rose 28.47% to Rs 198.32 crore in the year ended March 2025 as against Rs 154.37 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 61.2344.82 37 198.32154.37 28 OPM % 23.8315.80 - 15.8715.64 - PBDT 14.696.23 136 37.5822.70 66 PBT 13.845.30 161 34.4719.35 78 NP 10.403.59 190 26.7014.60 83
